Feb 20, 2019 - Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Feb 19, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10.9 million of Shares, Stocks: MRK, release date:Feb 19, 2019
Feb 19, 2019 - A drug that disappointed in 2018 will get an unexpected dance at the big ball.
Feb 18, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.
Feb 13, 2019 - Top Research Reports for ExxonMobil, Merck & Danaher
Feb 12, 2019 - Bristol-Myers' (BMY) oncology drug, Sprycel in combination with chemotherapy gets EC approval to treat pediatric patients with newly diagnosed Ph+ ALL.
Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
Feb 12, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.